BioCatalyst

GNLX — GENELUX Corp catalysts

2 verified catalyst event(s) for GENELUX Corp (ticker GNLX). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2026-12-01 — Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's C · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 27d
ESTIMATED
 READOUT
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Phy
Phase 3 · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
 GNLX GENELUX Corp olvimulogene nanivacirepvec, Platinum ch ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2027-02 (month)
in 3mo
ESTIMATED
 READOUT
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician'
Phase 2 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma
 GNLX GENELUX Corp Olvimulogene nanivacirepvec, Platinum ch ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.